2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Genomics, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Young Adult
PAPER

3906 Pro BNP identifies patients receiving Bruton tyrosine kinase inhibitors at risk for clinically significant arrhythmias

Christine Gruessner, MD MPH, Alessandra Brofferio, MD2, Emily B. Tomasulo, DO3, Ingrid Frey4, Laura Samples, MD5, Jeanine Superata, FNP-C6, Boeui Kang7, Said Hafizullah Fayaz, MD MSc8, Pia Nierman, RN9, Clare Sun, MD10, Mark Haigney, MD11, Adrian Wiestner, MD, PhD12
1 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
2 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
5 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
6 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
7 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
8 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
9 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States
12 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States

Background:

Bruton tyrosine kinase inhibitors (BTKi) are associated with atrial and ventricular arrhythmias that may lead to treatment discontinuation, cardiovascular morbidity, and sudden death. There are currently no standard cardiac assessments prior to or during treatment with a BTKi. Extended ambulatory electrocardiographic monitoring can identify otherwise unrecognized arrhythmias, but routine monitoring of all BTKi-treated patients is resource intensive. We prospectively performed systematic cardiac screening to identify clinically significant arrhythmias and their clinical, imaging, and biomarker correlates.

Methods:

We conduct a single-center prospective observational study of cardiac arrhythmias during treatment with BTK inhibitors or venetoclax (NCT05724121) compliant with the Declaration of Helsinki. Cohort B completed enrollment of patients receiving ibrutinib, acalabrutinib, or zanubrutinib. Cardiac evaluation included resting electrocardiogram (EKG), transthoracic echocardiogram, stress EKG, 14-day ambulatory electrocardiographic monitoring, and a portable 6-lead EKG for symptoms. All studies were reviewed by a cardiologist and electrophysiologist. Clinically significant arrhythmias (CSA) were prespecified by protocol. Clinical variables, including pro-B-type natriuretic peptide (proBNP) and troponin, were measured at the cardiac evaluation. Clinical variable distributions were compared using the Wilcoxon rank-sum test. Discrimination was assessed by receiver-operating-characteristic analysis. Logistic regression evaluated the association per doubling of ProBNP and troponin. For proBNP, an exploratory threshold of 125 pg/mL was used to estimate sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

Results:

Fifty patients were evaluated: 23 receiving acalabrutinib, 15 ibrutinib, and 12 zanubrutinib. Median age was 70 years (range, 24–86), 31 (62%) were male, 48 (96%) had chronic lymphocytic leukemia, 2 (4%) had lymphoplasmacytic lymphoma, and median BTKi exposure was 52 months (range, 3–143). In 5 patients (4 on ibrutinib, 1 on acalabrutinib), CSAs were identified during screening: atrial fibrillation lasting >24 hours (n=3), ventricular ectopy with >2,000 premature ventricular complexes/24 hours (n=2), and polymorphic ventricular tachycardia (n=1); one patient met 2 criteria. BTKi therapy was discontinued in 4 of 5 patients, followed by resolution or reduced arrhythmia burden. Nine patients (18%) had non-clinically significant arrhythmias. No sudden cardiac deaths occurred.

ProBNP was higher in patients with CSAs than in those without (median, 292 [interquartile range, 266–495] vs 47 [18–116] pg/mL; p=0.002). ProBNP demonstrated strong discrimination for CSA (area under the curve [AUC], 0.93). Each doubling of proBNP was associated with increased odds of CSA (odds ratio, 5.66; 95% confidence interval, 1.38–23.10; p=0.016). At the exploratory threshold of 125 pg/mL (upper limit of normal), sensitivity was 100%, specificity 78%, PPV 33%, and NPV 100%. Fifteen patients (30%) had proBNP ≥125 pg/mL, and this subgroup contained all 5 patients with CSA. Thus, a proBNP-directed strategy would have selected 30% of the cohort for further work-up while identifying all clinically significant events observed. Affected patients had preserved or only mildly reduced left ventricular ejection fraction (range 44-65%), suggesting that overt systolic heart failure alone is unlikely to explain the observed proBNP elevations.

Although troponin concentrations were modestly higher among patients with clinically significant arrhythmias, discrimination was substantially inferior to proBNP (AUC 0.71 vs 0.93), suggesting that myocardial wall stress is a more informative biomarker than myocardial injury for identifying BTKi-associated clinically significant arrhythmias.

In conclusion, proBNP was strongly associated with clinically significant arrhythmias during BTKi therapy and demonstrated excellent discrimination and an observed sensitivity of 100% in this exploratory cohort. ProBNP may serve as a readily available triage biomarker to identify BTKi-treated patients who warrant extended ambulatory rhythm monitoring, potentially reducing monitoring burden while preserving detection of CSAs. The 125-pg/mL threshold was derived retrospectively and requires prospective validation in a larger independent cohort.
Christine Gruessner, MD MPH: No relevant conflicts of interest to declare.